
Preparedness in Practice – CCP Retreat 2026
On 24 May 2026, CCRG, in collaboration with ISARIC, hosted
A robust national critical care research ecosystem that drives innovation, improves patient outcomes and informs clinical practice and policy decisions by fostering collaboration, building research capacity, and translating discoveries into real-world solutions.
Our mission is to advance critical care research by fostering interdisciplinary collaborations, enhancing research capacity, and conducting high-quality, impactful studies. Through rigorous inquiry and innovation, we seek to address key challenges in critical care, translate research findings into improved patient care, and shape evidence-based clinical practices and healthcare policies across the nation.
Chair, Department of CCM, Ziauddin University, Karachi
MBBS, FFARCSI
[email protected]
Landline # 021-35862937-39, Ext # 4460
Profile:
Dr Madiha Hashmi is a Professor and Chair of the Department Critical Care Medicine at Ziauddin University, Karachi. She is also a Visiting Faculty at Aga Khan University Karachi, Pakistan; an Honorary Physician, Mahidol Oxford Research Unit (MORU), Bangkok, Thailand; and Secretary, Faculty of CCM at the College of Physicians and Surgeons Pakistan (CPSP).
Project Manager, ISARIC, and Clinical Research Coordinator, Department of CCM, Ziauddin University, Karachi
Master in Biological Sciences, Shaheed Zulfikar Ali Bhutto Institute of Science and Technology University (SZABIST), Karachi.
[email protected]
Profile/Projects:
Ms. Aasma Khan is responsible for managing the planning, execution, and coordination of all clinical research projects within the Critical Care Research Group. Ms Khan also serves as the Clinical Research Coordinator for the Antimicrobial Resistance Surveillance Network for Healthcare-associated Infections (ACORN-HAI) and leading the Clinical Characterization Protocol (CCP) by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) and World Health Organization (WHO) at Ziauddin University. Her research interests include Critical Care Epidemiology, Antimicrobial Resistance, and Infectious diseases.
Profile/Projects:
Dr. Sidra is the site coordinator for the ISARIC/WHO Clinical Characterization Protocol (CCP) for Severe Emerging Infections and Syndromes in Pakistan. She has contributed to the Evidence based Antimicrobial Stewardship Programme in the ICU (EQUIPS) , Out of pocket expense in the ICU (ICOPE), and the Dengue Prospective Surveillance Study. Her research interests focus mainly on infectious diseases.
Profile/Projects:
Dr. Mahmooda is currently serving as the Site Coordinator for the Infectious Acute Encephalitis Syndrome (iAES) Study, and has previously contributed as Site Coordinator for the EQUIPs Study and the ICoPe Project. Her research interests include critical care rehabilitation, post-ICU outcomes, and public health strategies to enhance patient and family engagement in intensive care settings.
Profile/Projects:
Mr. Azeem is leading the implementation of Good Financial Grant Practice standards through SOP and policy development and institutional process improvement. He previously served as a Clinical Research Coordinator at the Ziauddin University Clinical Trial Unit, supporting multiple Phase II–III international trials with regulatory submissions, CTA/budget negotiations, patient coordination, EDC management, and biosample handling. He has had foundational experience as a Trainee Biotechnologist.
Assistant Project Manager, ISARIC
Bachelor of Commerce, University of Sindh, Jamshoro.
Profile/Projects:
Mr Faraz serves as Assistant Project Manager for the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) project, within the Critical Care Research Group at Ziauddin University. His role includes maintaining budgets, tracking invoices, coordinating and facilitating communication between departments for management of different clinical research projects.
Professor Nikhat is a neuroscientist, biochemist, and former Dean of Research at Ziauddin University. Her research career spans over 38 years and crosses the entire research spectrum, from laboratory experiments to clinical studies on diseases such as diabetes, dementia, and blindness. She also meaningfully contributes to research ethics, training, policy development, and strategic planning. Beyond conducting scientific research, Prof. Nikhat is passionate about building capacity to enable high-quality and patient-centred research in Pakistan.
Dr. Timo is a Ph.D candidate based at the University of British Columbia in Canada and has worked as a regional clinical trial coordinator for several international intensive care trials across South Asia, including Malaysia, Nepal, and Pakistan. He is working collaboratively with researchers at Ziauddin University on making clinical trials more relevant for low-resource settings. Dr. Timo is focused on patient engagement, qualitative research, and health equity, and has a personal interest in the use of film to promote health and justice.
Research Associate, Department of CCM, Ziauddin University, Karachi
Ph.D in Biotechnology, University of Sindh, Jamshoro.
[email protected]
Profile/Projects:
Dr. Priya specialises in molecular research and coordinates multiple studies, including the Genetics of Mortality in Critical Care (GenOMICC) and an observational study to follow up patients with suspected or confirmed COVID-19. She is also the Co-Lead for the Dengue Prospective Surveillance in Ziauddin Group of Hospitals, where she plays a role in expanding the project to other institutes across Pakistan. Her research interest lies in identifying genetic aspects of Infectious diseases.
The Mega-ROX trial is a large-scale, multi-centre, randomised clinical study investigating optimal oxygen therapy strategies for mechanically ventilated adults in intensive care. Embedded within PRICE, this study examines whether a conservative approach to oxygen therapy reduces mortality compared to a liberal approach, while also exploring whether liberal oxygen therapy may benefit certain groups, such as patients with acute brain pathologies (excluding hypoxic brain injuries) and those with sepsis. Ziauddin University contributes to this global effort with an enrollment number of 236 patients, as of July 2024, with Pakistan accounting for 20% of the total enrollments.
GenOMICC investigates the genetic factors influencing susceptibility to life-threatening infections and sterile injuries. In collaboration with the International Severe Acute Respiratory Infection Consortium (ISARIC) and the International Forum of Acute Care Trialists (InFACT), this study aims to establish a DNA resource for genome-wide discovery of host genetic variants that affect patient outcomes. By analysing DNA samples from critically ill patients in Pakistan, the research seeks to identify key genetic mechanisms that could lead to new therapeutic targets for improving survival in severe infections and systemic injuries.
Ziauddin University is the coordinating centre for other GenOMICC sites, achieving 299 successful enrollments as of September 2024.
REMAP, is a Randomised, Embedded, Multifactorial, Adaptive Platform trial. The broad objective of this trial is, over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia. This trial is an innovative global research initiative designed to improve the treatment of community-acquired pneumonia (CAP) including COVID-19, particularly in severe cases that require admission to an Intensive Care Unit (ICU). REMAP-CAP uses an adaptive platform trial design that allows for the simultaneous testing of multiple treatments across different domains. The trial evolves by incorporating new treatment options and adjusting strategies based on real-time data.
Ziauddin University is the coordinating centre for other REMAP-CAP sites and successfully enrolled patients in the Vitamin C, Ivermectin, Statin, and Oseltamivir domains. In the Ivermectin domain, 98% of enrollments are from Pakistan.
The ISARIC-WHO Clinical Characterisation Protocol (CCP) is a standardised protocol for the
rapid, coordinated clinical investigation of severe or potentially severe illness caused by
emerging or high-consequence pathogens or other noxious exposures of public health interest.
It is an adaptable protocol depending on a site’s resources and works in a tiered approach:
○ Tier 0: Data collection
○ Tier 1: Data collection and on-admission samples
○ Tier 2 – 3: Data collection and serial sampling depending on resources
The following studies utilise CCP:
https://isaric.org/research/dengue/dengue-clinical-characterisation-protocol/
https://isaric.org/research/covid-19-clinical-research-resources/covid-19-long-term-follow-up-study/
Five waves of COVID-19: Insights from the Pakistan Registry of Intensive CarE (PRICE)
This is a multicentre prospective observational study analysing the demographics, clinical characteristics, and outcomes of 9,102 patients with SARS-CoV-2 infection admitted to 69 PRICE-collaborating intensive care units (ICUs) across Pakistan from April 2020 to March 2022 during the five waves of the pandemic.
ACORN-HAI is a surveillance designed to address the growing threat of antimicrobial resistance (AMR) in healthcare-associated infections (HAIs) within Pakistan. This project focuses on severe infections, particularly in intensive care units (ICUs), surgical wards, and cancer care settings, where multidrug-resistant organisms (MDROs) are most prevalent. The study aims to monitor and document the incidence and prevalence of AMR in HAIs, specifically focusing on bloodstream infections (BSI) and ventilator-associated pneumonia (VAP).
Ziauddin University has successfully implemented the study across both North and Clifton campuses and has enrolled 212 patients as of October 2024.
The Pakistan Registry of Intensive CarE (PRICE) is a network of more than eighty intensive care units (ICUs) across Pakistan, including both public and private sector institutions. Established as a clinician-led initiative, PRICE aims to standardise and improve critical care practices throughout the country. The registry prospectively collects clinical and demographic data on consecutive adult ICU admissions, providing detailed information on the case mix, including presentation, diagnosis, comorbidities, severity of illness, organ support days, ICU mortality, and care processes. It provides a platform for evaluating the quality of care, implementing quality improvement initiatives, and facilitating registry-based research and platform trials within Pakistani ICUs.
Oxygen requirements and approaches to respiratory support in patients with COVID-19 in low- and middle-income countries (O2CoV2) was an observational study conducted by WHO between March – April 2022. The study aimed to characterise type and duration of different modalities of oxygen therapy delivered to patients; describe demographics and outcomes of hospitalised patients with COVID-19; and describe facility-level oxygen production and support. The study was implemented in 30 countries representing four LMICs from each of the six WHO regions. Pakistan successfully contributed 67 enrolments.
A multicentre, randomised trial conducted between May 2020 and March 2022. It aimed to assess whether medical masks provided non-inferior protection compared to N95 respirators in preventing COVID-19 among healthcare workers. Participants were randomly assigned to wear either medical masks or fit-tested N95 respirators for 10 weeks. The study was conducted across 29 healthcare facilities in Canada, Israel, Pakistan, and Egypt, involving 1,009 healthcare workers. Of these, 186 participants were from Pakistan.




















The Good Financial Grant Practices (GFGP) project is part of the broader work under the ISARIC 3.0 Programme (Grant Number: 303666/Z/23/Z). The initiative aims to strengthen institutional systems at Ziauddin University, Pakistan, by embedding the GFGP framework to improve financial governance, transparency, and accountability in research funding.
The project is further supported through a British Council grant titled “Strengthening Outbreak Research in Pakistan: Embedding Good Organisational Financial Governance using Good Financial Grant Practice (GFGP)”, valued at £40,000. It is being implemented in collaboration with the University of Oxford, led by Genevieve Kiff in collaboration with the Office of Research Innovation and Commercialisation (ORIC) at Ziauddin University. Through policy alignment, capacity building, and joint training between ZU and Oxford, the project supports rapid and transparent deployment of research funds during health emergencies while strengthening preparedness for disease outbreaks in low- and middle-income countries.
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) has been awarded a funding of £16.5 million (Grant Number: 303666/Z/23/Z) by Wellcome/FCDO/Gates Foundation. This is supporting a five-year programme (2024–2029) involving ISARIC’s strategic agenda for the year 2024-2029, organised into 3 strategic integrated platforms: The Clinical Research Platform (I), Research Interoperability & Acceleration Platform (II), and the Capacity Sharing & Research Quality Improvement Platform (III). The South Asian Hub, led by Dr. Madiha Hashmi, builds sustainable research capacity through shared protocols, rapid study activation, and coordinated regional efforts.

This one-year grant, awarded in July 2024 by World Health Organisation valued at £11,356 (Grant Number: PSR00280), supports the development of a WHO maturity framework for clinical trials units (CTUs) to assess and strengthen national and institutional clinical research capacity.
The framework will guide the development and piloting of a model that will help countries and institutions evaluate their current resources and plan targeted enhancements to conduct high-quality, robust clinical trials and strengthen the broader clinical research ecosystem.
Ziauddin University was awarded a Public Engagement Bursary of £10,000 (Grant Number: A-20-0007/003) by the Mahidol Oxford Tropical Medicine Research Unit (MORU) in 2023, for the “Establishment of a Public and Patient Involvement and Engagement (PPIE) Group in a Clinical Trials Unit in Pakistan.” Led by Dr. Timo Tolppa and Dr. Arishay Hussaini in collaboration with global partners, this 14-month grant project successfully established Pakistan’s first PPIE group to support clinical trials.
Comprising patient caregivers and community representatives, the group has made meaningful contributions to the informed consent processes for international trials such as Mega-ROX and REMAP-CAP. Their input has helped make these processes more culturally appropriate, locally relevant, and accessible.
The 1.5-year DFID – Wellcome Epidemic Preparedness grant, awarded in 2021, was valued at £337,159, of which CCRG received £48,674 (Grant Number: 222048/Z/20/Z). It has supported the successful rollout of the ISARIC Clinical Characterisation Protocol (CCP) across LMICs. The project has strengthened clinical research capacity by enabling implementation in multiple regions across three continents including South Asia, with Pakistan serving as a key coordination hub.
Dr. Madiha Hashmi has been appointed as the Hub Lead for Pakistan to support rapid, standardised data collection during health emergencies, integrate data systems like REDCap, and streamline dashboard reporting, with the option to share aggregated data with WHO to strengthen global infectious disease preparedness. The CCP was also embedded into the PRICE platform during COVID-19, making it a valuable tool for collecting COVID-19 data from 69 ICUs all over Pakistan.
The South Asian Hub lead by Professor Hashmi has taken initiatives to improve patient care in Pakistan by standardising data collection processes, which has led to the identification of gaps in patient management and fostered an informed ‘community of healthcare professionals’ within the network. Expanding on ISARIC’s preparedness endeavours and leveraging established connections within the Pakistan Registry of Intensive Care (PRICE), the integration of the ISARIC WHO Case Report Form into the PRICE registry has significantly enhanced data gathering efforts across 80 ICUs. This pioneering approach, which embeds data collection mechanisms within existing registries, enabled the REMAP-CAP collaborative to carry out their trial for COVID. Regular reports on outcomes of COVID-19 patients admitted to ICUs empowered healthcare professionals with valuable insights to optimise patient care.
Additionally, the Karachi Hub established a comprehensive framework for follow-up studies, incorporating approaches involving patient communities, including implementing follow-up calls post-discharge with access to medical professionals, and designing concise, user-friendly questionnaires for telephone surveys.
The Critical Care Research Team has been awarded the prestigious WHO-SHQ-RFP-24-2020 grant for their proposal to create a globally applicable Clinical Trials Unit (CTU) maturity framework. The project will focus on developing standards and guidance for CTUs, ensuring their capacity to manage high-quality clinical trials in diverse settings. The framework will be piloted across multiple WHO regions, enhancing its global applicability and impact.

On 24 May 2026, CCRG, in collaboration with ISARIC, hosted

From 31st January – 3rd February 2026, Jinnah Postgraduate Medical

Ziauddin University proudly hosted a two-day workshop on the Good

The “Training of Trainers (ToT) – Business Process Mapping” workshop

The programme began with Stage I: web-based learning (September–October 2025),

The “Building Global Acute Care Research Capacity” conference held in

On 7th September 2025, the Critical Care Research Group (CCRG),

Ziauddin University successfully hosted the face-to-face training of the Clinical

The Pakistan Registry of Intensive CarE (PRICE) is a national

On 20 May, the doors of the Clinical Trials Unit

To celebrate International Clinical Trials Day on 20 May 2024,











